NCT01634763 2020-12-19
Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Novartis
Phase 1 Completed
Clinical Trials
1 trialsPhase 1 × Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) × Clear all